Author details

Full Name

Anna Maria Storniolo

Affiliation

ORCID

Career Start Year

1987

Papers

146

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36534524	Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial.	Clin Cancer Res	2023
37589839	Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes.	Breast Cancer Res Treat	2023
37652539	Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial).	J Nucl Med	2023
37709737	Stromal heterogeneity may explain increased incidence of metaplastic breast cancer in women of African descent.		2023
38059556	Signaling Pathway Alterations Driven by BRCA1 and BRCA2 Germline Mutations are Sufficient to Initiate Breast Tumorigenesis by the PIK3CAH1047R Oncogene.		2023
36585450	Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis.	Nat Cancer	2023
37014487	Breast Cancer Worry in U.S. Female First-degree Relatives: Moderating Role of Daily Spiritual Experiences.		2023
37195235	A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer.	Clin Cancer Res	2023
37433282	Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts.	Cancer Cell	2023
37430354	Exploring breast tissue microbial composition and the association with breast cancer risk factors.	Breast Cancer Res	2023
35139887	Aberrant epigenetic and transcriptional events associated with breast cancer risk.	Clinical Epigenetics	2022
35821041	Towards defining morphologic parameters of normal parous and nulliparous breast tissues by artificial intelligence.	Breast Cancer Res	2022
35503494	Serum hormone levels and normal breast histology among premenopausal women.	Breast Cancer Res Treat	2022
35801147	Racial Differences in Cumulative Disadvantage Among Women and Its Relation to Health: Development and Preliminary Validation of the Cumulative Stress Inventory of Women's Experiences.	Health Equity	2022
35551360	Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer.	Clinical Cancer Research	2022
35418123	The impact of reproductive factors on DNA methylation-based telomere length in healthy breast tissue.	NPJ Breast Cancer	2022
36400020	Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts.	Cancer Cell	2022
35776183	Genome-wide association study of aromatase inhibitor discontinuation due to musculoskeletal symptoms.	Support Care Cancer	2022
36457510	Automated lesion detection of breast cancer in [<sup>18</sup>F] FDG PET/CT using a novel AI-Based workflow.	Front Oncol	2022
34977686	Acquisition, processing, and single-cell analysis of normal human breast tissues from a biobank.	STAR Protocols	2022
34910554	BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer.	J Clin Oncol	2022
35209953	Evidence of accelerated epigenetic aging of breast tissues in patients with breast cancer is driven by CpGs associated with polycomb-related genes.	Clinical Epigenetics	2022
35183258	FAM83A is a potential biomarker for breast cancer initiation.	Biomarker Research	2022
34716198	A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609).	Clin Cancer Res	2022
34400413	Inhibiting Fatty Acid Synthase with Omeprazole to Improve Efficacy of Neoadjuvant Chemotherapy in Patients with Operable TNBC.	Clin Cancer Res	2021
33999652	Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer.	J Clin Oncol	2021
34045233	First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer.	Molecular Cancer Therapeutics	2021
34096894	Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activity.	Pharmacogenet Genomics	2021
33771849	The Effects of Lifetime Estrogen Exposure on Breast Epigenetic Age.	Cancer Epidemiol Biomarkers Prev	2021
33763657	A single-cell atlas of the healthy breast tissues reveals clinically relevant clusters of breast epithelial cells.	Cell Reports Medicine	2021
33063774	Relations of Mindfulness and Illness Acceptance With Psychosocial Functioning in Patients With Metastatic Breast Cancer and Caregivers.	Oncology Nursing Forum	2020
32070401	TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer.	Breast Cancer Res	2020
32164769	Estimating breast tissue-specific DNA methylation age using next-generation sequencing data.	Clin Epigenetics	2020
31822498	TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR Metastatic Triple-Negative Breast Cancer.	Clinical Cancer Research	2020
31662331	TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer.	Clin Cancer Res	2020
31858384	A Computational Statistics Approach to Evaluate Blood Biomarkers for Breast Cancer Risk Stratification.	Hormones and Cancer	2020
33038501	Protocol of a randomized trial of acceptance and commitment therapy for fatigue interference in metastatic breast cancer.	Contemporary Clinical Trials	2020
32644110	Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.	JAMA Oncol	2020
33083529	Upregulation of lipid metabolism genes in the breast prior to cancer diagnosis.	npj Breast Cancer	2020
32964115	Polygenic risk score for the prediction of breast cancer is related to lesser terminal duct lobular unit involution of the breast.	NPJ Breast Cancer	2020
31190621	Effects of <i>SLCO1B1</i> polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozole.	Pharmacogenomics	2019
30747308	Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion.	Breast Cancer Res Treat	2019
31079282	Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapy.	Breast Cancer Res Treat	2019
30862719	Free Fatty Acids Rewire Cancer Metabolism in Obesity-Associated Breast Cancer via Estrogen Receptor and mTOR Signaling.	Cancer Research	2019
30721110	TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer.	J Clin Oncol	2019
30718355	Genetic Ancestry-dependent Differences in Breast Cancer-induced Field Defects in the Tumor-adjacent Normal Breast.	Clinical Cancer Research	2019
30992305	Dual TGFÎ²/BMP Pathway Inhibition Enables Expansion and Characterization of Multiple Epithelial Cell Types of the Normal and Cancerous Breast.	Molecular Cancer Research	2019
27464353	Factors underlying metastatic breast cancer patients' perceptions of symptom importance: a qualitative analysis.	European Journal of Cancer Care	2018
28918548	Tumor and serum DNA methylation in women receiving preoperative chemotherapy with or without vorinostat in TBCRC008.	Breast Cancer Res Treat	2018
30071865	A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer.	Breast Cancer Res	2018